Our global product portfolio includes many medicines that are innovative leaders in their therapeutic areas.
Our portfolio addresses a range of therapeutic areas.
In cardio metabolic we focus on diseases that negatively affect the heart, kidney, liver and blood vessels with the goal of better patient outcomes.
For more information about heart failure, raise awareness and join our public awareness campaign please visit KeepItPumping.com
In ophthalmology, we focus on innovative products in areas of high unmet medical need, which is retina, glaucoma, and dry eye diseases, to improve eye health and enhance people’s lives.
Our offering includes services for blind and visually impaired people, especially the ViaOpta Apps, which are available in App Stores for free.
In respiratory we build on a strong heritage of meeting the needs of primary care patients and focus on improving the lives of the hundreds of millions of people living with respiratory diseases, including chronic obstructive pulmonary disease (COPD) and severe allergic asthma.
In neuroscience we have a strong 60-year history. We currently offer patients and physicians a large drug portfolio encompassing multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, epilepsy and attention deficit hyperactivity disorder (ADHD).
For more information about our outreach to multiple sclerosis patients, please visit www.livinglikeyou.com.
Immunology and dermatology
In immunology and dermatology we are transforming patients’ lives by preventing progressive illnesses and successfully treating co-morbidities in the specialty dermatology, rheumatology and transplantation fields, where there remain high unmet medical needs.
For more information about our commitment to help people with ankylosing spondylitis, please visit: www.thisaslife.com.
More information for patients with psoriatic arthritis is available at www.psaandme.com.
In oncology we are a leader in driving the practice of precision oncology treatment. Precision oncology is the evolving understanding of how cancers develop on a genomic level and our ability to develop drugs that hone in on those targets – ultimately leading to better patient outcomes.
For more information on our commitment to transform the way people live with cancer and targeted diseases, visit www.novartisoncology.com.